GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

Modern weight loss medications represent a breakthrough, but they are most effective when combined with the right lifestyle ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

When Zepbound, Eli Lilly's highly anticipated weight loss drug, hit the market a year and a half ago, it marked a turning point for the accessibility of weight loss drugs. Since then, Zepbound, the ...

A new weight-loss drug promises to offer powerful results for Americans struggling with obesity, potentially surpassing the success patients have seen with Ozempic and Wegovy.. Zepbound, which was ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...